



Tao Liu, MD^{1*}; Guang Zeng, MD^{1,2*}; Huangheng Tao, PhD^{3*}; Yue Shi, MD^{1*}; COVID-19
in Cancer Patients Research Group^{1,4}; Ting Wang, BS^{1†}; Tongzu Liu, MD, PhD^{1†};
Fangjian Guo, MD, PhD^{5,6†}; Fuling Zhou, MD^{7†}; Xinghuan Wang, MD^{1,2†}

¹Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei

²Leishenshan Hospital, Wuhan, Hubei

³State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST)
and Key Laboratory for Oral Biomedicine of Ministry of Education (KLOBM), School and
Hospital of Stomatology, Wuhan University, Wuhan, Hubei

⁴Cancer Precision Diagnosis and Treatment and Translational Medicine, Hubei
Engineering Research Center, Zhongnan Hospital of Wuhan University, Wuhan, China

⁵Department of Obstetrics & Gynecology, The University of Texas Medical Branch at
Galveston, Galveston, TX

⁶Center for Interdisciplinary Research in Women's Health, The University of Texas
Medical Branch at Galveston, Galveston, TX

⁷Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei

* Contributing equally as first authors

† Contributing equally as senior authors

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ijc.33148

Members of COVID-19 in Cancer Patients Research Group include: Tao Liu, MD¹; Yue Shi, MD¹; Hongjie Shi, MD⁴; Xiaoyue Zhang, MD⁴; Wenjun Ding, MD⁴; Yang Li, MD⁴; Xi Tong, MD⁴

Correspondence to: Xinghuan Wang, MD

Department of Urology
Zhongnan Hospital of Wuhan University
No. 169 Donghu Road, Wuchang District
Wuhan, Hubei 430071, China
Email: wangxinghuan@whu.edu.cn

and

Fangjian Guo, MD, PhD

Department of Obstetrics & Gynecology
Center for Interdisciplinary Research in Women's Health
The University of Texas Medical Branch at Galveston
301 University Blvd
Galveston, TX 77555-0587
Tel: (409) 772-8599
Email: faguo@utmb.edu

and

Fuling Zhou, MD

Department of Hematology
Zhongnan Hospital of Wuhan University
No. 169 Donghu Road, Wuchang District

Wuhan, Hubei 430071, China

Email: zhoufuling@whu.edu.cn

Abbreviations

COVID-19	Coronavirus disease in 2019
IgG	Immunoglobulin G
IgM	Immunoglobulin M
RT-PCR	Reverse transcription polymerase chain reaction
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2

Statements and disclosures:

Funding

Part of the study was supported by National Key Research and Development Program of China (2020YFC0845500, principal investigator: Dr. X. Wang). Dr. F. Guo is supported by the National Cancer Institute of National Institute of Health under Award Number K07CA222343. The content is solely the responsibility of the authors and does not necessarily represent the official views of the sponsors.

Role of the Funder/Sponsor

The sponsors had no role in the design and conduct of the study; collection,

management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication.

Conflict of interest

The authors have no conflict of interest to disclose.

Data Accessibility

The data that support the findings of this study are available from the corresponding authors upon reasonable request.

Ethics approval

The study was approved by the institutional ethics board at Zhongnan Hospital of Wuhan University. Requirement for written informed consent was waived by the institutional ethics board.

Author Contributions: Dr. X. Wang, Dr. F. Zhou, Dr. Tongzu Liu and Ms. T. Wang had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs. Tao Liu, G. Zeng, H. Tao, and Y. Shi contributed equally to the study. Ms. T. Wang, Dr. Tongzu Liu, Dr. F. Guo, Dr. F Zhou and Dr. X. Wang contributed equally as senior authors.

Concept and design: X. Wang, F. Zhou, Tongzu Liu and T. Wang. Acquisition, analysis, or interpretation of data: Tao Liu, G. Zeng, H. Tao, Y. Shi, H. Shi, X. Zhang, W. Ding, Y.

Li and X. Tong. Drafting of the manuscript: Tao Liu, G. Zeng, H. Tao, Y. Shi, and F. Guo.
Critical revision of the manuscript for important intellectual content: X. Wang, F. Zhou,
Tongzu Liu and T. Wang. Statistical analysis: Tao Liu and G. Zeng.

Dear Editor,

Currently, coronavirus disease in 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. In patients infected with SARS-CoV-2, IgM antibodies are detectable around 7 days post infection and IgG antibodies usually take two weeks to develop.¹⁻³ COVID-19 IgM/IgG tests have been developed around the world for the diagnosis and management of COVID-19 patients, identifying convalescent cases, and sero-epidemiological surveillance.⁴ It is reported that cancer patients with COVID-19 often get more severe symptoms and have higher mortality risk^{5,6}. It is unknown whether there is a difference in the prevalence of IgG antibodies to SARS-CoV-2 between cancer patients and other COVID-19 patients. In this study, we assessed prevalence of IgG antibodies against SARS-CoV-2 in cancer patients with COVID-19 and other hospitalized COVID-19 patients from Zhongnan Hospital of Wuhan University, Wuhan No. 7 Hospital, and Leishenshan Hospital in Wuhan, China.

The study was approved by the institutional ethics board at Zhongnan Hospital of Wuhan University. Requirement for written informed consent was waived by the

institutional ethics board. There were 1603 hospitalized patients with COVID-19 who received both COVID-19 IgM/IgG tests and Reverse transcription polymerase chain reaction (RT-PCR) tests for SARS-CoV-2 from February 29 to April 5, 2020. Eighty-four patients were transferred from Zhongnan Hospital of Wuhan University to Leishenshan Hospital and were only counted once each. We excluded 133 patients with COVID-19 whose IgM/IgG tests were less than 21 days after symptom onset to allow enough time for IgG antibodies against SARS-CoV-2 to develop. In total, we included 40 cancer patients with COVID-19 and 1430 other hospitalized COVID-19 patients.

Diagnosis of COVID-19 was based on epidemiological history, clinical manifestations and presence of SARS-CoV-2 in clinical samples confirmed by using real-time RT-PCR method.⁷ There were changes in diagnosis of COVID-19 in China during time, and the case definition was gradually broadened to all for detection of milder cases.⁸ The confirmed cases were estimated to be 4 times less than that if the later broader case definition had been adopted earlier. All the 1470 patients in our study were hospitalized COVID-19 patients confirmed by RT-PCR tests for SARS-CoV-2. Severity of status of patients with COVID-19 at admission was defined as moderate, severe, or critical. Patients with mild diseases were not admitted to the above three hospitals and were generally admitted to Fangcang Hospitals (makeshift hospitals).

Serum samples from these people were collected. Methods for testing serum IgM and IgG antibodies to SARS-CoV-2 were previously described.⁹ COVID-19 IgM/IgG test kits contained recombinant SARS-CoV-2 antigens (spike protein and nucleocapsid protein)

labelled with magnetic beads (tested on a fully-automated chemiluminescence immunoassay analyzer) or colloidal gold (test card), anti-human IgM monoclonal antibody, and anti-human IgG monoclonal antibody. These test kits were reported to have high sensitivity and specificity^{9,10}. According to the manufacturers, the sensitivity and specificity are ~90% and >99% for IgM, and ~98% and ~98% for IgG, respectively.

Several physicians extracted the following data using data collection form from electronic medical records: demographic information such as age and sex, RT-PCR test date and results, COVID-19 IgM/IgG test date and results, date of symptom onset for COVID-19 patients, and clinical characteristics. Another physician in the research team reviewed the collected data.

Continuous variables were reported using mean and 95% confidence interval (CI) if normally distributed or median and interquartile range if nonnormally distributed. Means for normally-distributed continuous variables were compared using Student's t-test. Mann-Whitney test was used for assessing differences of nonnormal-distributed variables. Categorical variables were described as frequency rates and percentages. The χ^2 test was used for the comparison of categorical variables and Fisher's exact test was used when frequency was too low. Prevalence of positive IgM/IgG test results and 95% CI was also reported. For the assessment of RT-PCR test results of SARS-CoV-2 and IgM/IgG test results, the last test result for each person was used in the analyses. Differences in prevalence of IgM/IgG antibodies to SARS-CoV-2 between cancer patients and other patients were assessed by Wald χ^2 test using logistic regression

models. Statistical analyses were conducted using SAS software version 9.4 (SAS Institute; Carey, NC). A 2-sided p value of <0.05 was considered statistically significant.

There were no differences in age and sex in cancer patients with COVID-19 and other COVID-19 patients (**Table S1**). IgG prevalence was 72.5% (95% CI 58.0-87.0%) in cancer patients with COVID-19 compared to 90.3% (95% CI 88.7-91.8%) in other patients ($p<0.001$, **Table 1**). IgM prevalence was 20.0% (95% CI 7.0-33.0%) in cancer patients with COVID-19 and 31.7% (95% CI 29.3-34.1%) in other patients.

Among cancer patients, none was positive for SARS-CoV-2 by RT-PCR test. Presence of IgG antibodies to SARS-CoV-2 was not associated with severity of COVID-19 at first presentation or other clinical characteristics (**Table S2**).

We assessed prevalence of IgG antibodies to SARS-CoV-2 in cancer patients with COVID-19 and found that only 72.5% had IgG antibodies to SARS-CoV-2 after 21 days post symptom onset, much lower than patients without cancer. It's reported that after 17-19 days post symptom onset, IgG was positive in all patients with COVID-19.³ Lack of blood samples >17 days post symptom onset may be responsible for negative IgG tests in some patients reported in previous literatures. However, this may not apply to cancer patients. Whether they did not get seroconversion or lose the IgG antibodies to SARS-CoV-2 is to be investigated. Currently, the role of IgG antibodies to SARS-CoV-2 in the immune response against the virus infection is unclear. It is hard to interpret the finding of the low prevalence of IgG antibodies to SARS-CoV-2 in cancer patients.

References

1. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*. 2020:1-10.
2. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579(7798):270-273.
3. Long Q-X, Liu B-Z, Deng H-J, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nature Medicine*. 2020:1-4.
4. Yong SEF, Anderson DE, Wei WE, et al. Connecting clusters of COVID-19: an epidemiological and serological investigation. *Lancet Infect Dis*. 2020.
5. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol*. 2020;21(3):335-337.
6. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *Jama*. 2020.
7. Deng SQ, Peng HJ. Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. *J Clin Med*. 2020;9(2).
8. TK T, P W, Y L, EHY L, GM L, BJ C. Effect of Changing Case Definitions for COVID-19 on the Epidemic Curve and Transmission Parameters in Mainland China: A Modelling Study. *The Lancet Public health*. 2020;5(5).
9. Zeng H, Xu C, Fan J, et al. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia. *JAMA*. 2020.
10. Li Z, Yi Y, Luo X, et al. Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis. *J Med Virol*. 2020.

Table 1. Prevalence of IgM and IgG antibodies to SARS-CoV-2 among cancer patients with COVID-19 and other hospitalized COVID-19 patients.

	Prevalence % (95% Confidence Interval)		P value
	Cancer Patients	COVID-19 Patients	
	(n=40)	(n=1430)	
Prevalence IgG			
All	72.5 (58.0-87.0)	90.3 (88.7-91.8)	<0.001
Age group (years)			
≤70	67.7 (50.3-85.2)	91.2 (89.6-92.9)	<0.001
>70	88.9 (63.3-100.0)	86.4 (82.4-90.5)	0.83
Sex			
Female	72.7 (52.5-92.9)	90.9 (88.8-93.0)	0.008
Male	72.2 (49.3-95.1)	89.7 (87.4-91.9)	0.026
Prevalence IgM			
All	20.0 (7.0-33.0)	31.7 (29.3-34.1)	0.12
Age group (years)			
≤70	12.9 (0.4-25.4)	30.6 (27.9-33.3)	0.043
>70	44.4 (3.9-85.0)	36.1 (30.4-41.7)	0.61
Sex			
Female	9.1 (0.0-22.1)	28.1 (24.8-31.4)	0.068
Male	33.3 (9.2-57.5)	35.4 (31.8-38.9)	0.86

Low prevalence of IgG antibodies to SARS-CoV-2 in cancer patients with COVID-19

Tao Liu*; Guang Zeng*; Huangheng Tao*; Yue Shi*; COVID-19 in Cancer Patients Research Group; Ting Wang[†]; Tongzu Liu[†]; Fangjian Guo[†]; Fuling Zhou[†]; Xinghuan Wang[†]

* Contributing equally as first authors

[†] Contributing equally as senior authors

Members of COVID-19 in Cancer Patients Research Group include: Tao Liu; Yue Shi; Hongjie Shi; Xiaoyue Zhang; Wenjun Ding; Yang Li; Xi Tong

Table of Contents

Table S1	Page 2
Table S2	Page 3

Table S1. Characteristics of cancer patients with COVID-19 and other hospitalized COVID-19 patients.

	Mean (95% Confidence Interval), Median (Interquartile Range), or n (%)		P values
	Cancer Patients	COVID-19 Patients	
	(n=40)	(n=1430)	
Mean Age (years)	61.0 (56.8-65.2)	58.7 (57.9-59.4)	0.3
Age group (years)			
≤70	31 (77.5)	1150 (80.4)	0.65*
>70	9 (22.5)	280 (19.6)	
Sex			
Female	22 (55.0)	723 (50.6)	0.58*
Male	18 (45.0)	707 (49.4)	
Days from symptom onset to IgM/IgG test	39(30-53)	41(33-49)	0.89
Days from symptom onset to RT-PCR test	31(27-34)	39(34-43)	0.11

Age was reported as mean (95% confidence interval). P value for the difference was from Student's t-test.

Days from symptom onset to IgM/IgG test and days from symptom onset to RT-PCR test were summarized as median and interquartile range. P values for the differences were from Mann-Whitney tests.

* P value from the χ^2 test.

Table S2. Characteristics of cancer patients with COVID-19 by IgG antibodies to SARS-CoV-2 status.

	Mean (95% CI) or n (%)		
	Positive	Negative	P Value
	(n=29)	(n=11)	
Age (years)	61.8 (56.6-67.1)	58.8 (51.3-66.4)	0.52
Age group (years)			
≤70	21 (72.4)	10 (90.9)	0.4*
>70	8 (27.6)	1 (9.1)	
Sex			
Female	16 (55.2)	6 (54.5)	0.97*
Male	13 (44.8)	5 (45.5)	
Severity of COVID-19 at admission			
Moderate	20 (69.0)	9 (81.8)	0.69*
Severe	9 (31.0)	2 (18.2)	
Clinical characteristics			
Progression to critical status			
No	27 (93.1)	9 (81.8)	0.3*
Yes	2 (6.9)	2 (18.2)	
ICU admission			
No	27 (93.1)	10 (90.9)	0.81*
Yes	2 (6.9)	1 (9.1)	
Death			
No	28 (96.6)	10 (90.9)	0.48*
Yes	1 (3.4)	1 (9.1)	

Positive: cancer patients who had IgG antibodies to SARS-CoV-2.

Negative: cancer patients who did not have IgG antibodies to SARS-CoV-2.

* P value from Fisher's exact test.